Annual report pursuant to Section 13 and 15(d)

Related Party Transactions - Additional Information (Detail)

v3.8.0.1
Related Party Transactions - Additional Information (Detail)
12 Months Ended
Nov. 08, 2017
USD ($)
Investor
$ / shares
shares
May 10, 2017
Investor
Dec. 29, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Investor
shares
Jun. 27, 2016
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 15, 2016
Sep. 14, 2016
Related Party Transaction [Line Items]                    
Number of accredited investors | Investor   3                
Cash received from sale of business               $ 1,450,000    
Cash received from related parties               250,000    
Share issued during period, value               2,640,147    
Accounts payable and accrued expenses             $ 39,457 524,620    
Maximum [Member] | Oral Mucositis ECC [Member]                    
Related Party Transaction [Line Items]                    
Debt instrument, term             12 months      
Series B Preferred Stock [Member]                    
Related Party Transaction [Line Items]                    
Convertible shares Preferred stock, number of common stock upon conversion | shares 1,320,000                  
Convertible preferred stock, terms of conversion Conversion of one share of Series B Preferred Stock into two shares of Common Stock.                  
Reverse stock split, conversion ratio of Preferred stock into Common stock 2                  
Purchase price per share of Preferred Stock, as per share of Common Stock | $ / shares $ 2.50                  
Common Stock [Member]                    
Related Party Transaction [Line Items]                    
Share issued during period, value               $ 905    
Intrexon [Member]                    
Related Party Transaction [Line Items]                    
Percentage of outstanding common stock               31.50%    
Intrexon [Member] | Lantibiotic ECC [Member]                    
Related Party Transaction [Line Items]                    
Cash paid to Intrexon Corporation             $ 594 $ 548,994    
Intrexon [Member] | Oral Mucositis ECC [Member]                    
Related Party Transaction [Line Items]                    
Cash paid to Intrexon Corporation             524,026 932,645    
Intrexon [Member] | Unsecured Non-convertible Promissory Note [Member]                    
Related Party Transaction [Line Items]                    
Debt instrument, face amount $ 2,400,000                  
Debt instrument, converted amount $ 3,400,000                  
Debt instrument, term   2 years                
Interest rate   12.00%                
Intrexon [Member] | Series C Preferred Stock [Member]                    
Related Party Transaction [Line Items]                    
Number of share issued as a result of conversion of convertible securities | shares 100                  
Intrexon [Member] | Series C Preferred Stock [Member] | Lantibiotic ECC [Member]                    
Related Party Transaction [Line Items]                    
Share issued during period, value             1,188      
Intrexon [Member] | Series C Preferred Stock [Member] | Oral Mucositis ECC [Member]                    
Related Party Transaction [Line Items]                    
Share issued during period, value             763,189      
ProBiora Health, LLC [Member]                    
Related Party Transaction [Line Items]                    
Cash received from related parties             $ 10,388 $ 26,333    
ProBiora Health, LLC [Member] | Transition Services Agreement [Member]                    
Related Party Transaction [Line Items]                    
Management fee             3.00%      
Agreement term             90 days      
Subletting rate per month             $ 1,623      
Sublease expiration date             Feb. 28, 2017      
ProBiora Health, LLC [Member] | Discontinued Operations Disposed of by Sale [Member]                    
Related Party Transaction [Line Items]                    
Interest rate           1.00%        
Sales price of business           $ 1,700,000        
Cash received from sale of business           1,250,000        
Receivable from sale of business           $ 450,000        
Contingent consideration payment period           10 years        
ProBiora Health, LLC [Member] | Discontinued Operations Disposed of by Sale [Member] | Maximum [Member]                    
Related Party Transaction [Line Items]                    
Contingent consideration           $ 2,000,000        
KFLP [Member]                    
Related Party Transaction [Line Items]                    
Percentage of outstanding common stock               34.50%    
Principal Owner [Member] | Intrexon [Member]                    
Related Party Transaction [Line Items]                    
Percentage of outstanding common stock             32.00% 32.00%    
Accounts payable and accrued expenses             $ 39,457 $ 524,620    
Private Placement [Member] | Series B Preferred Stock [Member]                    
Related Party Transaction [Line Items]                    
Proceeds from issuance of convertible preferred stock $ 3,300,000                  
Number of accredited investors | Investor 4                  
Warrants to purchase common stock | shares 1,064,518                  
Private Placement [Member] | Fall 17 Warrant [Member] | Series B Preferred Stock [Member]                    
Related Party Transaction [Line Items]                    
Warrants to purchase common stock | shares 1,064,518                  
Term of warrants 7 years                  
Non-exercisable term of warrants 6 months                  
Warrants exercise price per share | $ / shares $ 3.10                  
Private Placement [Member] | Common Stock [Member]                    
Related Party Transaction [Line Items]                    
Number of accredited investors | Investor         3          
Issuance date         Jun. 30, 2016          
Shares issued | shares         904,568          
Proceeds from issuance         $ 4,667,000          
Private Placement [Member] | Common Stock [Member] | Dr. Frederick Telling [Member]                    
Related Party Transaction [Line Items]                    
Shares issued | shares         96,918          
Private Placement [Member] | Intrexon [Member] | Common Stock [Member]                    
Related Party Transaction [Line Items]                    
Shares issued | shares         226,142          
Private Placement [Member] | KFLP [Member]                    
Related Party Transaction [Line Items]                    
Interest rate                 6.00% 3.00%
Cash received from related parties     $ 1,000,000 $ 1,000,000            
Extended maturity date of notes payable               Dec. 31, 2016    
Private Placement [Member] | KFLP [Member] | Series B Preferred Stock [Member]                    
Related Party Transaction [Line Items]                    
Number of convertible preferred stock and warrants purchased by investors | shares 1,500,000                  
Warrants to purchase common stock | shares 241,936                  
Private Placement [Member] | KFLP [Member] | Common Stock [Member]                    
Related Party Transaction [Line Items]                    
Interest rate         3.00%       6.00% 3.00%
Shares issued | shares         581,508          
Note receivable due from sale of common stock         $ 2,000,000          
Cash received from related parties     $ 1,000,000 $ 1,000,000            
Extended maturity date of notes payable               Dec. 31, 2016